aspartic acid has been researched along with irinotecan in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Arioka, H; Fukumoto, H; Fukuoka, K; Ishida, T; Iwamoto, Y; Kurokawa, H; Narita, N; Nishio, K; Saijo, N; Suzuki, T; Tomonari, A; Usuda, J | 1 |
| Ando, M; Hanioka, N; Ishida, S; Jinno, H; Nishimura, T; Ozawa, S; Saeki, M; Saito, Y; Sawada, J; Tanaka-Kagawa, T | 1 |
| Ando, M; Hanioka, N; Jinno, H; Kaniwa, N; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tanaka-Kagawa, T; Yoshida, T | 1 |
| Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Brünner, N; Bunch, L; Christensen, S; Jensen, AA; Jensen, NF; Pedersen, SF; Pedraz-Cuesta, E; Romer, MU; Stenvang, J | 1 |
1 trial(s) available for aspartic acid and irinotecan
| Article | Year |
|---|---|
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
5 other study(ies) available for aspartic acid and irinotecan
| Article | Year |
|---|---|
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aspartic Acid; Camptothecin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase Inhibitors; Caspases; Cyclin A; Cyclin-Dependent Kinase Inhibitor p16; DNA Fragmentation; DNA, Complementary; Enzyme Activation; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Protease Inhibitors; S Phase; Time Factors; Transfection; Tumor Cells, Cultured | 2000 |
Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Topics: Amino Acid Substitution; Animals; Arginine; Aspartic Acid; Camptothecin; Chlorocebus aethiops; COS Cells; Genetic Variation; Glucuronides; Glucuronosyltransferase; Glutamine; Glycine; Humans; Irinotecan; Proline; Tyrosine | 2003 |
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Asparagine; Aspartic Acid; Camptothecin; COS Cells; Exons; Genetic Variation; Glucuronates; Glucuronic Acid; Glucuronosyltransferase; Humans; Irinotecan; Japan; Mutation; Neoplasms; Polymorphism, Single Nucleotide; Transfection; UDP-Glucuronosyltransferase 1A9 | 2003 |
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Topics: Amino Acid Transport System X-AG; Antineoplastic Agents; Aspartic Acid; Camptothecin; Cell Death; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Copper; Drug Resistance, Neoplasm; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 3; Gene Expression; Gene Knockdown Techniques; Glutathione; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein Transport; Tumor Suppressor Protein p53 | 2015 |